Synergistic therapeutic strategies and engineered nanoparticles for anti-vascular endothelial growth factor therapy in cancer

Khafaga, Asmaa F.; Gaballa, Mohamed M.S.; Karam, Reham; Shoulah, Salma A.; Shamma, Rehab N.; Khalifa, Norhan E.; Farrag, Nehal E.; Noreldin, Ahmed E.

doi:10.1016/j.lfs.2024.122499

Cited by 4 publications

(1 citation statement)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic platforms based on NPs have emerged as revolutionary approaches in cancer treatment, offering satisfying clinical outcomes while minimizing side effects [ 18 , 19 ] Gastrointestinal cancers are among the leading causes of cancer-related mortality worldwide. Since early diagnosis of these malignancies is often challenging due to the absence of clear symptoms, most patients have a poor prognosis of less than a year [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Illuminating new possibilities: Effects of copper oxide nanoparticles on gastrointestinal adenocarcinoma cells in hypoxic condition

Talebian,

Shahnavaz,

Shakiba

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Illuminating new possibilities: Effects of copper oxide nanoparticles on gastrointestinal adenocarcinoma cells in hypoxic condition

Talebian,

Shahnavaz,

Shakiba

et al. 2024

Heliyon

View full text Add to dashboard Cite

Proangiogenic potential of plasma exosomes from prostate cancer patients

Wang,

Zhou,

Wang

et al. 2024

Cellular Signalling

View full text Add to dashboard Cite

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Rahman,

Ali

2024

Cancers

View full text Add to dashboard Cite

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years in the median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing the formation of new vasculature (antiangiogenic treatments) or destroying formed tumor vasculature (vascular disrupting agents) show promise. This study summarizes the existing knowledge regarding the processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses the activation of redundant proangiogenic pathways, heightened tumor cell invasion and metastasis, resistance induced by hypoxia, creation of vascular mimicry channels, and regulation of the tumor immune microenvironment. Subsequently, we explore potential strategies to overcome this resistance, such as combining antiangiogenic therapies with other treatment methods, personalizing treatments for each patient, focusing on new therapeutic targets, incorporating immunotherapy, and utilizing drug delivery systems based on nanoparticles. Additionally, we would like to discuss the limitations of existing methods and potential future directions to enhance the beneficial effects of antiangiogenic treatments for patients with GBM. Therefore, this review aims to enhance the research outcome for GBM and provide a more promising opportunity by thoroughly exploring the mechanisms of resistance and investigating novel therapeutic strategies.

show abstract

Synergistic therapeutic strategies and engineered nanoparticles for anti-vascular endothelial growth factor therapy in cancer

Cited by 4 publications

References 210 publications

Illuminating new possibilities: Effects of copper oxide nanoparticles on gastrointestinal adenocarcinoma cells in hypoxic condition

Illuminating new possibilities: Effects of copper oxide nanoparticles on gastrointestinal adenocarcinoma cells in hypoxic condition

Proangiogenic potential of plasma exosomes from prostate cancer patients

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Contact Info

Product

Resources

About